Health in India is not merely a private concern; it is a public responsibility and a constitutional promise. The right to life under Article 21 of the Indian Constitution implicitly includes the right to health, a right that binds the State to protect citizens from harm — whether caused by disease, neglect, or deception. Yet today, this very right is under quiet assault, not from a failing healthcare system, but from an unchecked flood of false medical advertising on digital platforms.

On the surface, such ads may seem harmless — catchy videos on YouTube or posts on Facebook claiming that an herbal capsule can “cure diabetes in 30 days” or that an Ayurvedic syrup can “eliminate cancer naturally.” But beneath the marketing gloss lies a profound public health and legal crisis. These advertisements are not simply misleading; they erode the foundations of evidence-based medicine, exploit vulnerable patients, and challenge the credibility of India’s regulatory institutions.

The Drugs and Magical Remedies (Objectionable Advertisements) Act, 1954 (DMRA) was crafted precisely to prevent such exploitation. It prohibits any advertisement making false claims about curing serious diseases such as cancer, diabetes, infertility, or mental disorders. But the law was written for a different era — a time when communication moved slowly and accountability could be traced to print and broadcast media. The digital revolution has rendered this legislation nearly ineffective.

Platforms like YouTube, Instagram, and Google have transformed health misinformation into a business model. Their algorithms promote content that generates the most engagement — and it is often the most sensational, unscientific, and deceptive claims that attract the highest attention. This is not an accident of technology; it is an outcome of profit logic. Platforms earn from clicks and views, not from truth.

The problem is compounded by the legal fiction of “intermediary immunity” under the Information Technology Act, 2000, which shields digital platforms from liability for third-party content. Originally meant to protect them from being blamed for what users posted, this provision has now become a legal escape route for corporations that actively host and profit from “sponsored” or “paid” advertisements. When a company takes money to run a health ad, it ceases to be a neutral intermediary — it becomes a publisher, and should be held accountable.

India’s enforcement capacity under the DMRA remains weak. There is no central body dedicated to monitoring digital health advertisements, no technical framework for automated detection, and no real-time coordination between agencies. Complaints move slower than content does. By the time authorities issue a notice, the ad has disappeared or re-emerged under a new name. This cycle of regulatory futility has allowed a parallel market of miracle cures to thrive — unregulated, profitable, and invisible to accountability.

Contrast this with global norms. In the United States, the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) require every medical advertisement to be backed by scientific evidence. The European Union imposes steep fines for any unverified therapeutic claims. Even in Australia, the Therapeutic Goods Administration monitors online advertising rigorously. Strikingly, the same multinational firms that comply with these standards abroad routinely flout them in India — promoting untested “herbal solutions” for everything from infertility to cancer. This double standard exposes not just a gap in enforcement, but a lack of respect for Indian consumers’ rights.

Jurisdictional complexity adds another layer. Most of the digital platforms hosting these ads are based outside India. Their Indian subsidiaries claim limited operational roles, often disclaiming policy responsibility. When Indian regulators seek accountability, they encounter the fog of cross-border corporate structure, where decisions are made offshore and liability remains diffuse. The result: a global marketplace without a global regulator.

Algorithmic advertising adds yet another complication. Ads today are dynamic — tailored to each user’s search history, medical queries, and location. A person looking for diabetes treatment online will quickly find themselves targeted by “miracle cure” ads, invisible to anyone else. This micro-targeting makes detection and evidence collection difficult, as the content morphs constantly and disappears after short cycles. Regulation designed for static advertisements cannot keep up with this fluidity.

India has taken some steps in the right direction. The Central Consumer Protection Authority (CCPA) issued guidelines in 2022 to curb misleading advertisements and hold celebrities and influencers accountable for endorsements. The Ministry of AYUSH has also urged stricter implementation of the DMRA. But these efforts are reactive — responding to violations after the damage is done. What India needs is a forward-looking, preventive framework that blends technology with accountability.

First, digital platforms must be legally recognised as publishers when they host or profit from paid medical advertisements, not as neutral intermediaries.

Second, violations of the DMRA should be classified as serious offences, attracting stronger penalties and faster adjudication.

Third, India must invest in AI-based monitoring tools capable of detecting prohibited medical claims across languages and formats in real time.

Fourth, international cooperation mechanisms must be established so that foreign companies can be held accountable for advertisements targeting Indian users.

Finally, public education is indispensable. Citizens need to be taught to question and verify medical claims, especially on social media. Regulation can only succeed if consumers are aware and vigilant.

The issue here is not a rejection of traditional medicine or alternative healing. It is a demand for truthful communication and evidence-based accountability. Ayurveda and other systems of medicine have legitimate contributions to make — but their credibility is weakened when unscrupulous actors exploit them for commercial gain through unverified digital advertising.

India’s challenge is, therefore, both ethical and constitutional. The freedom to trade cannot override the right to health. Economic gain cannot come at the cost of public safety. In a democracy, truth in healthcare is not optional — it is a duty.

If India truly wishes to uphold the right to health, it must ensure that this right extends beyond hospitals and laboratories into the virtual spaces where health information now lives and spreads. False cures may offer instant hope, but they erode trust, distort science, and endanger lives.

In a digital society, the health of democracy itself depends on the health of truth. And truth, like medicine, demands careful regulation, not casual profit.